Abstract

Described herein are methods for inhibiting the acute relapse or worsening of glomerular disease in response to viral infections associated with the common cold or flu comprising administration of anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, or blocking agents to a subject in need thereof. Also described are methods for depleting a subjects systemic levels of one or more of cytokines IL-2, IL-6, IL-10, INF-γ, or TNFα, or inhibiting the receptors IL-4R or ICAM-1 comprising contacting the cytokines or receptors with one or more anti-cytokine antibodies, anti-receptor antibodies, soluble receptors, or blocking agents.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present disclosure provides a polypeptide and method for treating and/or preventing nephrotic syndrome, such as but not limited to those associated with minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 1/00 - General processes for the preparation of peptides
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/12 - Cyclic peptides
• C07K 14/765 - Serum albumin, e.g. HSA
• A61K 38/42 - HaemoglobinsMyoglobins
• A61K 35/16 - Blood plasmaBlood serum
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 14/76 - Albumins
• A61K 38/38 - Albumins
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/515 - Angiogenic factorAngiogenin
• C07K 14/775 - Apolipopeptides
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Abstract

The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• C07K 14/76 - Albumins
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 7/08 - Plasma substitutesPerfusion solutionsDialytics or haemodialyticsDrugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 3/06 - Antihyperlipidemics
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 1/00 - General processes for the preparation of peptides
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/12 - Cyclic peptides
• C07K 14/765 - Serum albumin, e.g. HSA
• A61K 38/42 - HaemoglobinsMyoglobins
• A61K 35/16 - Blood plasmaBlood serum
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 14/515 - Angiogenic factorAngiogenin
• C07K 14/775 - Apolipopeptides
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Abstract

The present disclosure provides a method for treating and/or preventing a condition characterized as a nephrotic syndrome, such as but not limited to minimal change disease (MCD) and membranous nephropathy (MN), and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• C07K 14/76 - Albumins
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 7/08 - Plasma substitutesPerfusion solutionsDialytics or haemodialyticsDrugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 3/06 - Antihyperlipidemics
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 1/00 - General processes for the preparation of peptides
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• C07K 14/515 - Angiogenic factorAngiogenin
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/575 - Hormones
• A61K 38/22 - Hormones
• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones